XML 17 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Apr. 01, 2023
Mar. 26, 2022
Operating Activities:    
Net income $ 202,327 $ 211,592
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation 31,952 28,984
Amortization 11,463 12,228
Gain on sale or disposal of property and equipment (129) (1,129)
Unrealized foreign currency gains (867) (5,113)
Deferred income taxes (15,713) (25,996)
Stock compensation expense 20,732 24,706
Realized loss (gain) on marketable securities 20 (2)
Changes in operating assets and liabilities, net of acquisitions:    
Accounts receivable, net of allowance for doubtful accounts 46,873 238,134
Inventories 43,712 (134,807)
Other current and non-current assets 4,780 (1,628)
Accounts payable (4,202) (61,939)
Other current and non-current liabilities (67,405) (119,159)
Deferred revenue (1,876) (3,704)
Deferred costs 622 1,904
Income Taxes 6,921 21,563
Net cash provided by operating activities 279,210 185,634
Investing activities:    
Purchases of property and equipment (46,814) (59,715)
Proceeds from sale of property and equipment 142 1,131
Purchase of intangible assets (332) (547)
Purchase of marketable securities (18,684) (497,526)
Redemption of marketable securities 57,789 431,604
Acquisitions, net of cash acquired 0 (10,828)
Net cash used in investing activities (7,899) (135,881)
Financing activities:    
Dividends (139,847) (128,856)
Proceeds from issuance of treasury stock related to equity awards 0 20,146
Purchase of treasury stock related to equity awards (9,169) (14,610)
Purchase of treasury stock under share repurchase plan (43,273) 0
Net cash used in financing activities (192,289) (123,320)
Effect of exchange rate changes on cash and cash equivalents 3,387 (6,960)
Net increase (decrease) in cash, cash equivalents, and restricted cash 82,409 (80,527)
Cash, cash equivalents, and restricted cash at beginning of period 1,279,912 1,498,843
Cash, cash equivalents, and restricted cash at end of period $ 1,362,321 $ 1,418,316